Ambient

Molecular Formula : C15H18FNO2•HCl

Molecular Formula : C15H18FNO2•HCl

Molecular Formula : C10H14FN3O4

Molecular Formula : C10H14FN3O4

Molecular Formula : C10H14FN3O4

Molecular Formula : C10 H14 F N2 O8 P . xH3 N

Molecular Formula : C10 H14 F N2 O8 P . xH3 N

Molecular Formula : C22H24D5FN3O9P

Molecular Formula : C22H24D5FN3O9P

Molecular Formula : C8 H15 N O

Molecular Formula : C12 H16 N2 O

Molecular Formula : C18H24N2O7

Molecular Formula : C18H24N2O7

Molecular Formula : C18H24N2O7

Molecular Formula : C12 D4 H12 N2 O

Molecular Formula : C12 D4 H12 N2 O

Molecular Formula : C12 D4 H12 N2 O

Molecular Formula : C12 2H10 H6 N2 O

Molecular Formula : C12 2H10 H6 N2 O

Molecular Formula : C12 2H10 H6 N2 O

Molecular Formula : C12 H17 N2 O4 P

Molecular Formula : C12 H17 N2 O4 P

Molecular Formula : C12 H17 N2 O4 P

Molecular Formula : C12 H17 N2 O4 P

Molecular Formula : C12 2H4 H13 N2 O4 P

Molecular Formula : C12 2H4 H13 N2 O4 P

Prostate-specific membrane antigen (PSMA) also known as Folate hydrolase 1 (FOLH1), Folylpoly-gamma-glutamate carboxypeptidase (FGCP), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), is a type II membrane glycoprotein that is expressed in prostate tissue and to a lesser extent in the peripheral and central nervous system, small intestinal, and salivary gland tissues. PSMA has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. The catalytic activity of PSMA involves the release of unsubstituted C-terminal glutamyl residues, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates. PSMA is used as a diagnostic and prognostic indicator of prostate cancer, and as a possible marker for various neurological disorders such as schizophrenia, Alzheimer’s disease, and Huntington’s disease.

Prostate-specific membrane antigen (PSMA) also known as Folate hydrolase 1 (FOLH1), Folylpoly-gamma-glutamate carboxypeptidase (FGCP), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), is a type II membrane glycoprotein that is expressed in prostate tissue and to a lesser extent in the peripheral and central nervous system, small intestinal, and salivary gland tissues. PSMA has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. The catalytic activity of PSMA involves the release of unsubstituted C-terminal glutamyl residues, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates. PSMA is used as a diagnostic and prognostic indicator of prostate cancer, and as a possible marker for various neurological disorders such as schizophrenia, Alzheimer’s disease, and Huntington’s disease.

Prostate-specific membrane antigen (PSMA) also known as Folate hydrolase 1 (FOLH1), Folylpoly-gamma-glutamate carboxypeptidase (FGCP), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), is a type II membrane glycoprotein that is expressed in prostate tissue and to a lesser extent in the peripheral and central nervous system, small intestinal, and salivary gland tissues. PSMA has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. The catalytic activity of PSMA involves the release of unsubstituted C-terminal glutamyl residues, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates. PSMA is used as a diagnostic and prognostic indicator of prostate cancer, and as a possible marker for various neurological disorders such as schizophrenia, Alzheimer’s disease, and Huntington’s disease.

Prostate-specific membrane antigen (PSMA) also known as Folate hydrolase 1 (FOLH1), Folylpoly-gamma-glutamate carboxypeptidase (FGCP), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), is a type II membrane glycoprotein that is expressed in prostate tissue and to a lesser extent in the peripheral and central nervous system, small intestinal, and salivary gland tissues. PSMA has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. The catalytic activity of PSMA involves the release of unsubstituted C-terminal glutamyl residues, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates. PSMA is used as a diagnostic and prognostic indicator of prostate cancer, and as a possible marker for various neurological disorders such as schizophrenia, Alzheimer’s disease, and Huntington’s disease.

Prostate-specific membrane antigen (PSMA) also known as Folate hydrolase 1 (FOLH1), Folylpoly-gamma-glutamate carboxypeptidase (FGCP), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), is a type II membrane glycoprotein that is expressed in prostate tissue and to a lesser extent in the peripheral and central nervous system, small intestinal, and salivary gland tissues. PSMA has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. The catalytic activity of PSMA involves the release of unsubstituted C-terminal glutamyl residues, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates. PSMA is used as a diagnostic and prognostic indicator of prostate cancer, and as a possible marker for various neurological disorders such as schizophrenia, Alzheimer’s disease, and Huntington’s disease.

Prostate-specific membrane antigen (PSMA) also known as Folate hydrolase 1 (FOLH1), Folylpoly-gamma-glutamate carboxypeptidase (FGCP), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), is a type II membrane glycoprotein that is expressed in prostate tissue and to a lesser extent in the peripheral and central nervous system, small intestinal, and salivary gland tissues. PSMA has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. The catalytic activity of PSMA involves the release of unsubstituted C-terminal glutamyl residues, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates. PSMA is used as a diagnostic and prognostic indicator of prostate cancer, and as a possible marker for various neurological disorders such as schizophrenia, Alzheimer’s disease, and Huntington’s disease.

Molecular Formula : C21 H18 O4

Molecular Formula : C21 H18 O4

Molecular Formula : C11 H6 O3

Molecular Formula : C11 H6 O3

Molecular Formula : C11 H6 O3

Psyllium Husk, 85 Percent, 40-80 Mesh, Powder

Psyllium Husk, 85 Percent, 40-80 Mesh, Powder

Psyllium Husk, 85 Percent, 40-80 Mesh, Powder

Molecular Formula : C44H8F20N4Pt

Molecular Formula : C44H8F20N4Pt

Molecular Formula : C44H8F20N4Pt

Molecular Formula : C15H9FN2O3